Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.

Vande Walle L, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, Van Hauwermeiren F, Saavedra PHV, Šimon P, Šubrt V, Kostka L, Stivala CE, Pham VC, Staben ST, Yamazoe S, Konvalinka J, Kayagaki N, Lamkanfi M.

PLoS Biol. 2019 Sep 16;17(9):e3000354. doi: 10.1371/journal.pbio.3000354. [Epub ahead of print]

PMID:
31525186
2.

IRF2 transcriptionally induces GSDMD expression for pyroptosis.

Kayagaki N, Lee BL, Stowe IB, Kornfeld OS, O'Rourke K, Mirrashidi KM, Haley B, Watanabe C, Roose-Girma M, Modrusan Z, Kummerfeld S, Reja R, Zhang Y, Cho V, Andrews TD, Morris LX, Goodnow CC, Bertram EM, Dixit VM.

Sci Signal. 2019 May 21;12(582). pii: eaax4917. doi: 10.1126/scisignal.aax4917.

PMID:
31113851
3.

Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death.

Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, Brooks A, Xia S, Wu H, Kelliher MA, Berger SB, Gough PJ, Bertin J, Proulx MM, Goguen JD, Kayagaki N, Fitzgerald KA, Lien E.

Science. 2018 Nov 30;362(6418):1064-1069. doi: 10.1126/science.aau2818. Epub 2018 Oct 25.

4.

Caspase-11 auto-proteolysis is crucial for noncanonical inflammasome activation.

Lee BL, Stowe IB, Gupta A, Kornfeld OS, Roose-Girma M, Anderson K, Warming S, Zhang J, Lee WP, Kayagaki N.

J Exp Med. 2018 Sep 3;215(9):2279-2288. doi: 10.1084/jem.20180589. Epub 2018 Aug 22.

5.

ASC- and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages.

Lee BL, Mirrashidi KM, Stowe IB, Kummerfeld SK, Watanabe C, Haley B, Cuellar TL, Reichelt M, Kayagaki N.

Sci Rep. 2018 Feb 28;8(1):3788. doi: 10.1038/s41598-018-21998-3.

6.

Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K).

Castanedo GM, Blaquiere N, Beresini M, Bravo B, Brightbill H, Chen J, Cui HF, Eigenbrot C, Everett C, Feng J, Godemann R, Gogol E, Hymowitz S, Johnson A, Kayagaki N, Kohli PB, Knüppel K, Kraemer J, Krüger S, Loke P, McEwan P, Montalbetti C, Roberts DA, Smith M, Steinbacher S, Sujatha-Bhaskar S, Takahashi R, Wang X, Wu LC, Zhang Y, Staben ST.

J Med Chem. 2017 Jan 26;60(2):627-640. doi: 10.1021/acs.jmedchem.6b01363. Epub 2017 Jan 12.

PMID:
28005357
7.

The Yersinia pestis Effector YopM Inhibits Pyrin Inflammasome Activation.

Ratner D, Orning MP, Proulx MK, Wang D, Gavrilin MA, Wewers MD, Alnemri ES, Johnson PF, Lee B, Mecsas J, Kayagaki N, Goguen JD, Lien E.

PLoS Pathog. 2016 Dec 2;12(12):e1006035. doi: 10.1371/journal.ppat.1006035. eCollection 2016 Dec.

8.

GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes.

Aglietti RA, Estevez A, Gupta A, Ramirez MG, Liu PS, Kayagaki N, Ciferri C, Dixit VM, Dueber EC.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):7858-63. doi: 10.1073/pnas.1607769113. Epub 2016 Jun 23.

9.

Does caspase-12 suppress inflammasome activation?

Vande Walle L, Jiménez Fernández D, Demon D, Van Laethem N, Van Hauwermeiren F, Van Gorp H, Van Opdenbosch N, Kayagaki N, Lamkanfi M.

Nature. 2016 Jun 2;534(7605):E1-4. doi: 10.1038/nature17649. No abstract available.

PMID:
27251234
10.

Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling.

Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, Cuellar T, Haley B, Roose-Girma M, Phung QT, Liu PS, Lill JR, Li H, Wu J, Kummerfeld S, Zhang J, Lee WP, Snipas SJ, Salvesen GS, Morris LX, Fitzgerald L, Zhang Y, Bertram EM, Goodnow CC, Dixit VM.

Nature. 2015 Oct 29;526(7575):666-71. doi: 10.1038/nature15541. Epub 2015 Sep 16.

PMID:
26375259
11.

Caspase-11: arming the guards against bacterial infection.

Stowe I, Lee B, Kayagaki N.

Immunol Rev. 2015 May;265(1):75-84. doi: 10.1111/imr.12292. Review.

PMID:
25879285
12.

Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection.

Muñoz M, Eidenschenk C, Ota N, Wong K, Lohmann U, Kühl AA, Wang X, Manzanillo P, Li Y, Rutz S, Zheng Y, Diehl L, Kayagaki N, van Lookeren-Campagne M, Liesenfeld O, Heimesaat M, Ouyang W.

Immunity. 2015 Feb 17;42(2):321-331. doi: 10.1016/j.immuni.2015.01.011. Epub 2015 Feb 10.

13.

Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells.

Rutz S, Kayagaki N, Phung QT, Eidenschenk C, Noubade R, Wang X, Lesch J, Lu R, Newton K, Huang OW, Cochran AG, Vasser M, Fauber BP, DeVoss J, Webster J, Diehl L, Modrusan Z, Kirkpatrick DS, Lill JR, Ouyang W, Dixit VM.

Nature. 2015 Feb 19;518(7539):417-21. doi: 10.1038/nature13979. Epub 2014 Dec 3.

PMID:
25470037
14.

Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFN-induced GTPases.

Meunier E, Dick MS, Dreier RF, Schürmann N, Kenzelmann Broz D, Warming S, Roose-Girma M, Bumann D, Kayagaki N, Takeda K, Yamamoto M, Broz P.

Nature. 2014 May 15;509(7500):366-70. doi: 10.1038/nature13157. Epub 2014 Apr 16.

PMID:
24739961
15.

Noncanonical inflammasome activation by intracellular LPS independent of TLR4.

Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, Miyake K, Zhang J, Lee WP, Muszyński A, Forsberg LS, Carlson RW, Dixit VM.

Science. 2013 Sep 13;341(6151):1246-9. doi: 10.1126/science.1240248. Epub 2013 Jul 25.

16.

Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1.

Broz P, Ruby T, Belhocine K, Bouley DM, Kayagaki N, Dixit VM, Monack DM.

Nature. 2012 Oct 11;490(7419):288-91. doi: 10.1038/nature11419. Epub 2012 Aug 15.

17.

Phosphorylation of NLRC4 is critical for inflammasome activation.

Qu Y, Misaghi S, Izrael-Tomasevic A, Newton K, Gilmour LL, Lamkanfi M, Louie S, Kayagaki N, Liu J, Kömüves L, Cupp JE, Arnott D, Monack D, Dixit VM.

Nature. 2012 Oct 25;490(7421):539-42. doi: 10.1038/nature11429. Epub 2012 Aug 12.

PMID:
22885697
18.

Phosphorylation-dependent activity of the deubiquitinase DUBA.

Huang OW, Ma X, Yin J, Flinders J, Maurer T, Kayagaki N, Phung Q, Bosanac I, Arnott D, Dixit VM, Hymowitz SG, Starovasnik MA, Cochran AG.

Nat Struct Mol Biol. 2012 Jan 15;19(2):171-5. doi: 10.1038/nsmb.2206.

PMID:
22245969
19.

Non-canonical inflammasome activation targets caspase-11.

Kayagaki N, Warming S, Lamkanfi M, Vande Walle L, Louie S, Dong J, Newton K, Qu Y, Liu J, Heldens S, Zhang J, Lee WP, Roose-Girma M, Dixit VM.

Nature. 2011 Oct 16;479(7371):117-21. doi: 10.1038/nature10558.

PMID:
22002608
20.

Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis.

Jones JW, Kayagaki N, Broz P, Henry T, Newton K, O'Rourke K, Chan S, Dong J, Qu Y, Roose-Girma M, Dixit VM, Monack DM.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9771-6. doi: 10.1073/pnas.1003738107. Epub 2010 May 10.

21.

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.

Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D.

Cell. 2007 Nov 16;131(4):669-81.

22.

DUBA: a deubiquitinase that regulates type I interferon production.

Kayagaki N, Phung Q, Chan S, Chaudhari R, Quan C, O'Rourke KM, Eby M, Pietras E, Cheng G, Bazan JF, Zhang Z, Arnott D, Dixit VM.

Science. 2007 Dec 7;318(5856):1628-32. Epub 2007 Nov 8.

23.

Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation.

Zhou H, Monack DM, Kayagaki N, Wertz I, Yin J, Wolf B, Dixit VM.

J Exp Med. 2005 Nov 21;202(10):1327-32.

24.

TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice.

Cretney E, McQualter JL, Kayagaki N, Yagita H, Bernard CC, Grewal IS, Ashkenazi A, Smyth MJ.

Immunol Cell Biol. 2005 Oct;83(5):511-9.

PMID:
16174101
25.

Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors.

Kasuga C, Ebata T, Kayagaki N, Yagita H, Hishii M, Arai H, Sato K, Okumura K.

Cancer Sci. 2004 Oct;95(10):840-4.

26.

Molecular cloning, functional characterization, and enzyme-linked immunosorbent assay of cynomolgus monkey Fas ligand.

Kirii Y, Inoue T, Yoshino K, Kayagaki N, Yagita H, Okumura K, Shibata H, Yoshikawa Y, Terao K.

J Immunol Methods. 2003 Jul;278(1-2):201-9.

PMID:
12957408
27.

Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL).

Kayagaki N, Yamaguchi N, Abe M, Hirose S, Shirai T, Okumura K, Yagita H.

Cell Immunol. 2002 Oct;219(2):82-91.

PMID:
12576026
28.

Expression of TNF-related apoptosis inducing ligand (TRAIL) on infiltrating cells and of TRAIL receptors on salivary glands in patients with Sjögren's syndrome.

Matsumura R, Umemiya K, Kagami M, Tomioka H, Tanabe E, Sugiyama T, Sueishi M, Kayagaki N, Yagita H, Okumura K.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6):791-8.

PMID:
12508770
29.

TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.

Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A, Takahashi K, Kagami K, Yamaguchi N, Yagita H, Okumura K, Koyama-Okazaki T, Suzuki T, Sugita K, Nakazawa S.

Blood. 2003 May 1;101(9):3658-67. Epub 2002 Dec 27.

30.

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2.

Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, Grewal IS, Cochran AG, Gordon NC, Yin J, Starovasnik MA, Dixit VM.

Immunity. 2002 Oct;17(4):515-24.

31.

Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice.

Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki N, Yun T, Smolak P, Le T, Goodwin R, Gliniak B.

Eur J Immunol. 2002 Aug;32(8):2246-54.

32.

Role of Fas/FasL pathway in the activation of infiltrating cells in murine acute myocarditis caused by Coxsackievirus B3.

Seko Y, Kayagaki N, Seino K, Yagita H, Okumura K, Nagai R.

J Am Coll Cardiol. 2002 Apr 17;39(8):1399-403.

33.

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development.

Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, Okumura K.

J Exp Med. 2002 Jan 21;195(2):161-9.

34.

Multiple pathways of TWEAK-induced cell death.

Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, Kominami E, Okumura K, Yagita H.

J Immunol. 2002 Jan 15;168(2):734-43.

35.

Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta.

Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, Yagita H, Okumura K, Tanaka N, Taniguchi T, Ogasawara K.

Eur J Immunol. 2001 Nov;31(11):3138-46.

36.

Protection against Fas-mediated and tumor necrosis factor receptor 1-mediated liver injury by blockade of FADD without loss of nuclear factor-kappaB activation.

Seino K, Setoguchi Y, Ogino T, Kayagaki N, Akiba H, Nakano H, Taniguchi H, Takada Y, Yuzawa K, Todoroki T, Fukuchi Y, Yagita H, Okumura K, Fukao K.

Ann Surg. 2001 Nov;234(5):681-8.

37.

Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.

Nisihara T, Ushio Y, Higuchi H, Kayagaki N, Yamaguchi N, Soejima K, Matsuo S, Maeda H, Eda Y, Okumura K, Yagita H.

J Immunol. 2001 Sep 15;167(6):3266-75.

38.

Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells.

Oshima K, Yanase N, Ibukiyama C, Yamashina A, Kayagaki N, Yagita H, Mizuguchi J.

Cytokine. 2001 May 21;14(4):193-201.

PMID:
11448118
39.

A protective role of PKCepsilon against TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in glioma cells.

Shinohara H, Kayagaki N, Yagita H, Oyaizu N, Ohba M, Kuroki T, Ikawa Y.

Biochem Biophys Res Commun. 2001 Jun 29;284(5):1162-7.

PMID:
11414705
40.

TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.

Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, Tokunaga K, Suzuki K, Kayagaki N, Yagita H, Hirai H, Juji T.

Blood. 2001 Apr 1;97(7):2067-74.

41.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.

Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, Yagita H, Okumura K.

J Exp Med. 2001 Mar 19;193(6):661-70.

42.

Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice.

Miura Y, Misawa N, Maeda N, Inagaki Y, Tanaka Y, Ito M, Kayagaki N, Yamamoto N, Yagita H, Mizusawa H, Koyanagi Y.

J Exp Med. 2001 Mar 5;193(5):651-60.

43.

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells.

Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H, Okumura K.

Nat Med. 2001 Jan;7(1):94-100.

PMID:
11135622
44.

Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity.

Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H.

J Exp Med. 2000 Nov 6;192(9):1373-80.

45.
46.

Skin-specific caspase-1-transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18.

Yamanaka K, Tanaka M, Tsutsui H, Kupper TS, Asahi K, Okamura H, Nakanishi K, Suzuki M, Kayagaki N, Black RA, Miller DK, Nakashima K, Shimizu M, Mizutani H.

J Immunol. 2000 Jul 15;165(2):997-1003.

47.

Treatment of lupus in NZB/W F1 mice with monoclonal antibody against Fas ligand.

Nakajima A, Hirai H, Kayagaki N, Yoshino S, Hirose S, Yagita H, Okumura K.

J Autoimmun. 2000 Mar;14(2):151-7.

PMID:
10677246
48.

Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.

Kim S, Kim KA, Hwang DY, Lee TH, Kayagaki N, Yagita H, Lee MS.

J Immunol. 2000 Mar 15;164(6):2931-6.

49.

Fas/Fas ligand-mediated apoptosis of murine Langerhans cells.

Kawamura T, Azuma M, Kayagaki N, Shimada S, Yagita H, Okumura K.

J Dermatol Sci. 2000 Feb;22(2):96-101.

PMID:
10674822
50.

Cytolytic mechanisms involved in non-MHC-restricted cytotoxicity in Chediak-Higashi syndrome.

Nakazawa T, Agematsu K, Yasui K, Onodera T, Inoue R, Kaneko H, Kondo N, Yamamoto M, Kayagaki N, Yagita H, Okumura K, Komiyama A.

Clin Exp Immunol. 1999 Oct;118(1):108-14.

Supplemental Content

Loading ...
Support Center